Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating on Diamedica Therapeutics (DMAC – Research Report) today. The company’s shares closed yesterday at $3.25.
According to TipRanks, Knickerbocker is a 3-star analyst with an average return of 3.4% and a 46.84% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Ironwood Pharma, Xtant Medical Holdings, and Avadel Pharmaceuticals.
Currently, the analyst consensus on Diamedica Therapeutics is a Strong Buy with an average price target of $6.50.
Based on Diamedica Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.16 million. In comparison, last year the company had a GAAP net loss of $3.75 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Diamedica Therapeutics (DMAC) Company Description:
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
